New research in a mouse model suggests that the drug rapamycin can reverse autism-like social deficits — but only if given early. The study is the first to shed light on the crucial timing of therapy to improve social impairments in a condition associated with autism spectrum disorder. Its findings could help inform future clinical trials in children with tuberous sclerosis complex.